Pharmacyclics Inc - Articles and news items

FDA grants Breakthrough designation to ibrutinib in cGVHD

Industry news / 1 July 2016 / Victoria White, Digital Content Producer

This marks the first time ibrutinib has been granted Breakthrough Therapy Designation for an indication beyond haematologic malignancies…

Ibrutinib shown to be superior to chlorambucil in trial

Industry news / 7 December 2015 / Victoria White

Data from a Phase 3 trial show ibrutinib was superior to chlorambucil in all efficacy endpoints measured in patients with CLL or SLL…

Supplemental New Drug Application for ibrutinib submitted to FDA

Industry news / 14 September 2015 / Victoria White

The supplemental New Drug Application has been submitted for front-line use of ibrutinib in patients with chronic lymphocytic leukaemia…

Bristol Myers Squibb logo

Bristol-Myers Squibb, Pharmacyclics and Janssen announce clinical collaboration to evaluate OPDIVO® (nivolumab) and IMBRUVICA®(ibrutinib) in non-Hodgkin lymphoma

Industry news / 13 October 2014 / Bristol-Myers Squibb Company

Bristol-Myers Squibb Company, Pharmacyclics, Inc., and Janssen Research & Development, LLC announced they have entered into a clinical trial collaboration agreement to evaluate the safety, tolerability and preliminary efficacy of Bristol-Myers Squibb’s investigational PD-1 immune checkpoint inhibitor OPDIVO® (nivolumab)…

Janssen Pharmaceuticals Logo

IMBRUVICA™ (ibrutinib) capsules now approved in the U.S. for Mantle Cell Lymphoma patients who have received at least one prior therapy

Industry news / 13 November 2013 / Johnson & Johnson

Single-agent oral therapy is one of the first medications to be approved via the U.S. Food and Drug Administration’s Breakthrough Therapy Designation Pathway…

Abbott logo

Abbott to collaborate with Janssen and Pharmacyclics

Industry news, News / 21 February 2013 / Abbott

Abbott will collaborate with Janssen Biotech and Pharmacyclics to explore the benefits of Abbott’s proprietary FISH technology…

Janssen Pharmaceuticals Logo

Janssen Biotech, Inc. announces collaborative development and worldwide license agreement for investigational anti-cancer drug, PCI-32765

Industry news, News / 8 December 2011 / Johnson & Johnson

Compound in development for multiple B-cell hematologic malignancies…


The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...